U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07678008) titled 'Prognostic Value of KELIM Score and Inflammatory Markers in Ovarian Cancer' on June 24.
Brief Summary: This is a retrospective observational study to evaluate the integrative prognostic value of inflammatory markers, specifically the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), alongside the CA-125 Elimination rate constant K (KELIM) score in advanced ovarian cancer patients. The study includes patients with advanced serous ovarian cancer (stage III or IV) who received neoadjuvant platinum-based chemotherapy followed by interval debulking surgery at Sohag University Hospital and Sohag Cancer Center between 2...